Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2022

View Archived Issues

NOS targeting to treat ischemic stroke

Serum PRO-C6 monitors and predicts infliximab response in patients with Crohn's disease

New TLR8 agonists identified at National Institute of Pharmaceutical R&D Co.

FLT3 inhibitors discovered at Cytosinlab Therapeutics

Janssen Pharmaceutica presents new factor XIa inhibitors

Roche patents vasopressin V1A receptor antagonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical identify new SOS1 inhibitors

Targeting sphingolipid synthesis has multiple beneficial effects in Duchenne model

SAF-248 shows potent activity against DLBCL in vitro and in vivo

STC-2 administration confers post-stroke functional recovery in a preclinical model

R2M3-26, a novel Wnt mimetic with promising efficacy in mouse model of colitis

3-beta-HSD linked to depression in males due to testosterone degradation

JN Nova advances COVID-19 therapeutic JN-2019 into clinic

T-cell evasion is one pressure shaping SARS-CoV-2 evolution

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...